SCHEMBL15613543

SCHEMBL15613543

Cn1cncc1COc1cc(F)cc(Oc2ccc(-c3nn(C4CCOCC4)c4ncnc(N)c34)cc2F)c1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 15/20 0.48
▸ PIK3CD O00329 13/20 0.48
▸ EGFR P00533 12/20 0.48
▸ ABL1 P00519 11/20 0.48
▸ HCK P08631 11/20 0.48
▸ KDR P35968 11/20 0.48
▸ PIK3CA P42336 11/20 0.48
▸ PIK3CB P42338 11/20 0.48
▸ MTOR P42345 11/20 0.48
▸ PIK3CG P48736 11/20 0.48
▸ EPHB4 P54760 11/20 0.48
▸ PRKDC P78527 11/20 0.48
▸ PI4KB Q9UBF8 9/20 0.48
▸ LCK P06239 3/20 0.45
▸ CSK P41240 2/20 0.45
▸ BTK Q06187 2/20 0.44
▸ CSNK1A1 P48729 1/20 0.44
▸ CSNK1D P48730 1/20 0.44
▸ CSNK1E P49674 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15613549 0.92 BTK (0.51) SRCPIK3CDEGFRABL1HCK
SCHEMBL16886161 0.90 PIK3CD (0.50) SRCPIK3CDEGFRABL1HCK
SCHEMBL15613503 0.87 BTK (0.50) BTK
SCHEMBL15613752 0.85 PIK3CD (0.48) SRCPIK3CDEGFRABL1HCK
SCHEMBL16886159 0.85 PIK3CD (0.49) SRCPIK3CDEGFRABL1HCK
SCHEMBL15613522 0.85 BTK (0.59) SRCPIK3CDEGFRABL1HCK
SCHEMBL16886130 0.85 BTK (0.50) SRCPIK3CDEGFRABL1HCK
SCHEMBL15613672 0.84 BTK (0.58) SRCPIK3CDEGFRABL1HCK
SCHEMBL15613629 0.84 BTK (0.36) SRCEGFRBTK
SCHEMBL15613544 0.83 BTK (0.49) SRCPIK3CDEGFRABL1HCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-9796716-B2 Selective inhibitors of Tec and Src protein kinase families PHARMASCIENCE, INC. (CA) 2017-10-24 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
US-20150191473-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2015-07-09 — — US disclosed
WO-2013177668-A1 PROTEIN KINASE INHIBITORS PHARMASCIENCE, INC. (CA) 2013-12-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191473-A1 PROTEIN KINASE INHIBITORS TEC, SRC, LCK SRC 2/4885PIK3CD 357/4885EGFR 521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback